NCT06125522
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Reclassified as terminated (was completed) Sponsor's reason: Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The planned Ph2 and DDI components were not initiated.
Minor Trial completed Show 5 more changesShow less
- Primary completion date changed from estimate of Dec 31, 2026 to Sep 10, 2026
- Study sites: 21 to 23
- Eligibility criteria expanded, about 13 words
- Secondary endpoints: details revised at 2 of 11 entries
- Collaborators: 2 to 3
- Notable Primary and study completion dates: Apr 30, 2026 to Dec 31, 2026
- Study sites revised (21)
- Minor Primary and study completion dates: Nov 4, 2025 to Apr 30, 2026
- Study sites revised (21)
- Minor Primary and study completion dates: Nov 3, 2025 to Nov 4, 2025v10
Show 8 earlier versionsHide 8 earlier versions
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 67 to confirmed 11
- Study sites: 47 to 21
- Primary and study completion dates moved earlier to Nov 3, 2025
- Minor Site details revised at 3 of 47 sitesv8
- Minor Study sites: 41 to 47v7
- Minor Study sites: 20 to 41v6
- Minor Study sites: 11 to 20
- Primary completion date: Feb 4, 2027 to Jul 23, 2026
- Study completion date: Aug 9, 2027 to Jan 25, 2027
- Notable Primary completion date: Aug 3, 2026 to Feb 4, 2027
- Study sites: 6 to 11
- Study completion date: Feb 2, 2027 to Aug 9, 2027
- Notable Phase: Phase 2 to Phase 1/2
- Study sites: 5 to 6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 4 to 5
- Start date changed from estimate of Nov 10, 2023 to Jan 10, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Phase 1b: Number of Participants With Dose Limiting Toxicities
Timeframe: 28 days
Drug Drug Interaction: To evaluate the effect of samuraciclib on PK of ARV 471.
Timeframe: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days)
Phase 2: Percentage of Participants With Objective Response by investigator assessment
Timeframe: Up to approximately 1 year
Drug Drug Interaction: • To evaluate the effect of ARV 471 on PK of samuraciclib.
Timeframe: From the start of Lead-in period (maximum 13 days) to the end of cycle 1 (at least 28 days))
Secondary (10)
Phase 1b, Drug drug interaction and Phase 2: Evaluation of Safety and Tolerability of ARV-471 in combination with Samuraciclib
Phase 1b: To evaluate antitumor activity of ARV-471 in combination with samuraciclib
Phase 1b and Phase 2: Duration of Response by investigator assessment.
Phase 1b and Phase2: Percentage of participants with Clinical Benefit Response by investigator assessment.
Phase 1b and Phase 2: Progression Free Survival by investigator assessment.
Show 5 moreShow less
Phase 1b and Phase 2: Plasma concentrations of ARV-471 and samuraciclib.
Phase 1b: Evaluation of effect of samuraciclib on PK of ARV-471
Phase 2:ctDNA plasma quantitative changes from pre-treatment
Phase 2: To evaluate the correlation between TP53 mutation status and antitumor activity
Phase 2: Overall Survival
Arms and interventions
ARV-471 in combination with SamuraciclibExperimental
ARV-471 administered orally QD continuously and Samuraciclib administered orally QD continuously on 28-day cycles
Drugs: vepdegestrant, Samuraciclib
Sites
23 sites in 4 countries
United States 19, Italy 2, Belgium 1, France 1